Literature DB >> 16916492

Reoperation for adrenocortical neoplasms.

James A Lee1, Quan-Yang Duh.   

Abstract

Adrenocortical cancer is a highly lethal malignancy. Surgical resection remains the only potential modality for cure or appreciable disease-free intervals. Even with radical resection, most patients will recur or have metastatic disease. For these patients, surgical re-resection of local recurrence and metastases is the best chance of controlling disease and prolonging survival. Patients with widely metastatic disease or those with tumors not amenable to re-resection may benefit from tumor debulking to help control symptoms associated with oversecretion syndromes. No currently available regimen of chemotherapy, including mitotane, and/or radiotherapy achieves significant cure or response rates. Multiple promising treatments such as radiofrequency ablation, tyrosine kinase inhibitors, and competitive inhibitors of multidrug resistance gene products are in preclinical trials and may improve patient outcomes.

Entities:  

Mesh:

Year:  2006        PMID: 16916492     DOI: 10.1007/s11864-006-0041-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  35 in total

1.  Andrenocortical carcinomas: twelve-year prospective experience.

Authors:  Libuse Tauchmanovà; Annamaria Colao; Luigi Antonio Marzano; Lucianna Sparano; Luigi Camera; Annalisa Rossi; Giovanna Palmieri; Ettore Marzano; Marco Salvatore; Guido Pettinato; Gaetano Lombardi; Riccardo Rossi
Journal:  World J Surg       Date:  2004-09       Impact factor: 3.352

2.  Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.

Authors:  T S Khan; H Imam; C Juhlin; B Skogseid; S Gröndal; S Tibblin; E Wilander; K Oberg; B Eriksson
Journal:  Ann Oncol       Date:  2000-10       Impact factor: 32.976

Review 3.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

4.  A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.

Authors:  Jame Abraham; Susan Bakke; Ann Rutt; Beverly Meadows; Maria Merino; Richard Alexander; David Schrump; David Bartlett; Peter Choyke; Rob Robey; Elizabeth Hung; Seth M Steinberg; Susan Bates; Tito Fojo
Journal:  Cancer       Date:  2002-05-01       Impact factor: 6.860

5.  Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy.

Authors:  J C Jensen; H I Pass; W F Sindelar; J A Norton
Journal:  Arch Surg       Date:  1991-04

Review 6.  Emerging treatment strategies for adrenocortical carcinoma: a new hope.

Authors:  Lawrence S Kirschner
Journal:  J Clin Endocrinol Metab       Date:  2005-10-18       Impact factor: 5.958

7.  Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.

Authors:  A Berruti; M Terzolo; A Pia; A Angeli; L Dogliotti
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

8.  Oral gossypol in the treatment of metastatic adrenal cancer.

Authors:  M R Flack; R G Pyle; N M Mullen; B Lorenzo; Y W Wu; R A Knazek; B C Nisula; M M Reidenberg
Journal:  J Clin Endocrinol Metab       Date:  1993-04       Impact factor: 5.958

9.  Survival rates and prognostic factors in adrenocortical carcinoma.

Authors:  P Icard; A Louvel; Y Chapuis
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

10.  Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature.

Authors:  M D Wooten; D K King
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.